Tag Archives: MRNA

The Delta Variant Gives Novavax an Outside Chance of Upside

Originally, when the novel coronavirus first became a thing, Novavax (NASDAQ:NVAX) showed great promise. While other vaccine developers were experimenting with pioneering nucleic-acid-based technologies, Novavax went with a subunit mechanism, a proven approach used in the hepatitis B vaccine. Theoretically, that should have been great news for NVAX stock and it was, at least for a while.

Source: Ascannio/Shutterstock.com

No matter how you look at it, Novavax is a Covid-19 winner. Prior to the pandemic, the company was staring at a complete implosion, having failed to deliver....More>>>

What Are the Prospects for Moderna?

Moderna’s (NASDAQ:MRNA) revenue and profits are soaring. Its share price is up more than 280% so far this year. The company plans to build its messenger RNA (mRNA) pipeline. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli address a viewer’s question about what the prospects are for Moderna going forward.

Keith Speights: John L. has a question, “What are the prospects for Moderna?” Ticker there, of course, is MRNA. Great ticker for that Moderna picked up there. John says, “I’ve been....More>>>

Why Moderna, BioNTech, and Novavax Stocks Sank Today

What happened

Shares of three leading COVID-19 vaccine makers sank on Thursday. As of the market close, BioNTech (NASDAQ:BNTX) stock was down 8.8%. Shares of Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) fell 5.8% and 4.2%, respectively.

None of the companies announced any developments. However, there were a couple of stories that were likely related to the vaccine stocks sinking.

CNBC reported that some scientists are criticizing the U.S. government’s decision to move forward with third booster doses of messenger RNA (mRNA) vaccines as premature. Also, results from....More>>>

Dual Wins for Pfizer Mean Big Jumps for These 2 Stocks

The stock market moved higher again on Monday morning, building on gains from Friday. Good news from Pfizer (NYSE:PFE) was encouraging to the broader market, as it inspired investors to believe they might be one step closer to the end of the COVID-19 pandemic. As of 11 a.m. EDT, the Dow Jones Industrial Average (DJINDICES:^DJI) was up 253 points to 35,373. The S&P 500 (SNPINDEX:^GSPC) gained 39 points to 4,480, and the Nasdaq Composite (NASDAQINDEX:^IXIC) picked up 187 points to 14,902.

Pfizer’s stock was among the best performers in the Dow on a percentage basis thanks to....More>>>

7 Stocks to Buy Following Vaccine Victories

The novel coronavirus has dealt a crippling blow to various industries and sectors, translating to tens of thousands of businesses. It’s impacted inflation, stock markets, labor markets, interest rates and a whole swath of other financial metrics. Surprisingly, though, there hasn’t been any shortage of stocks to buy.

The stock markets reacted to the initial Covid-19 trauma with a breathtaking and stunning decline. The S&P 500 fell about 35% inside of a month. However, the market found its footing and soared to the upside. It’s been grinding away at all-time highs....More>>>